Q2
CARL — Q2 2026 Financial Report Analysis
Carlsmed grew Q2 2026 revenue 57% to $18.9M on more personalized spine-implant procedures, but operating costs rose 66%, so the net loss widened to $10.5M even as the full-year revenue guide went up to $74–78M.